Kidney injury molecule-1

Current Opinion in Critical Care

Volumn 16, Issue 6, 2010, Pages 556-561

  Bonventre, Joseph V ^a,b   Yang, Li ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

acute kidney injury; kidney injury molecule 1; urinary biomarker

Indexed keywords

KIDNEY INJURY MOLECULE 1;

DRUG APPROVAL; HUMAN; KIDNEY INJURY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SENSITIVITY AND SPECIFICITY;

ACUTE KIDNEY INJURY; ANIMALS; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; CLINICAL TRIALS AS TOPIC; CRITICAL CARE; GRAFT REJECTION; HUMANS; INTENSIVE CARE UNITS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; KIDNEY TUBULES, PROXIMAL; MEMBRANE GLYCOPROTEINS; POSTOPERATIVE COMPLICATIONS; RECEPTORS, VIRUS; RENAL INSUFFICIENCY, CHRONIC; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 78649650462     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32834008d3     Document Type: Review

References (50)

1. Hubank M, Schatz DG. Identifying differences in mRNA expression by repre-sentational difference analysis of cDNA. Nucl Acid Res 1994; 22:5640-5648.
2. Ichimura T, Bonventre J V, Bailly V, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998; 273:4135-4142.
3. Ichimura T, Asseldonk EJ, Humphreys BD, et al. Kidney injury molecule-1 is a phosphatidylserine receptorthat confers a phagocytic phenotype on epithe-lial cells. J Clin Invest 2008; 118:1657-1668.
4. Bailly V, Zhang Z, Meier W, et al. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem 2002; 277:39739-39748.
5. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000; 407:784-788.
6. Gao PS, Mathias RA, Plunkett B, et al. Genetic variants of the T-cell immunoglobulin mucin 1 but not the T-cell immunoglobulin mucin 3 gene are associated with asthma in an African American population. J Allergy Clin Immunol 2005; 115:982-988.
7. Wu Q, Hu L, Cai P, et al. Association analysis of TIM-1-232GA and 5383-5397 insertion/deletion polymorphisms with childhood asthma and total serum immunoglobulin E levels in middle China. J Investig Allergol Clin Immunol 2009; 19:146-153.
8. Sonar SS, Hsu YM, Conrad ML, et al. Antagonism of TIM-1 blocks the development of disease in a humanized mouse model of allergic asthma. J Clin Invest 2010; 120:2767-2781.
9. Chae SC, Song JH, Shim SC, et al. The exon 4 variations of Tim-1 gene are associated with rheumatoid arthritis in a Korean population. Biochem Biophys Res Commun 2004; 315:971-975.
10. Yamanishi Y, Kitaura J, Izawa K, et al. TIM1 is an endogenous ligand for LMIR5/CD300b: LMIR5 deficiency ameliorates mouse kidney ischemia/reperfusion injury. J Exp Med 2010; 207:1501-1511.
11. Umetsu S E, Lee W L, McIntire J J, et al. TIM-1 inducesTcellactivationandinhibits the development of peripheral tolerance. Nat Immunol 2005; 6: 447-454.
12. Freeman GJ,Casasnovas J M, Umetsu DT, De Kruyff RH. TIMgenes:afamily of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 2010; 235:172-189.
13. Degauque N, Mariat C, Kenny J, et al. Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest2008; 118:735-741.
14. Ueno T, Habicht A, Clarkson MR, et al.Theemerging roleofTcell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest2008; 118:742-751.
15. Yuan X, Ansari MJ, D'Addio F, et al.Targeting Tim-1 toovercome resistanceto transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci USA 2009; 106:10734-10739.
16. Uchida Y, Ke B, Freitas MC, et al. The emerging role of Tcell immunoglobulin mucin-1 in the mechanism of liver ischemia and reperfusion injury in the mouse. Hepatology 2010; 51:1363-1372.
17. Bonventre JV, Vaidya VS, Schmouder R, et al. Next-generation biomarkers for detecting kidneytoxicity. Nat Biotechnol 2010; 28:436-440.
18. Ichimura T, Hung CC, Yang SA, et al. Kidney injury molecule-1: atissue and urinary biomarkerfor nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 2004; 286:F552-F563.
19. Zhou Y,Vaidya V S, Brown RP, et al. Comparison of kidney injury molecule-1 and othernephrotoxicity biomarkersin urineand kidneyfollowing acuteexposureto gentamicin, mercury, and chromium. Toxicol Sci 2008; 101:159-170.
20. Prozialeck WC, Vaidya VS, Liu J, et al. Kidney injury molecule-1 is an early biomarker of cadmium nephrotoxicity. Kidney Int 2007; 72:985-993.
21. Prozialeck WC. Toxicology and applied pharmacology. Foreword. Toxicol Appl Pharmacol 2009; 238:191.
22. Jost G, Pietsch H, Sommer J, et al. Retention of iodine and expression of biomarkers for renal damage in the kidney after application of iodinated contrast media in rats. Invest Radiol 2009; 44:114-123.
23. Perez-Rojas J, Blanco JA, Cruz C, et al. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2007; 292:F131-F139.
24. Nijboer WN, Schuurs T A, Damman J, et al. Kidney injury molecule-1 isan early noninvasive indicator for donor brain death-induced injury prior to kidney transplantation. Am J Transplant 2009; 9:1752-1759.
25. Van Timmeren MM, Bakker SJ, Vaidya VS, et al. Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Renal Physiol 2006; 291:F456-F464.
26. Tonomura Y, Tsuchiya N, Torii M, Uehara T. Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats. Toxicology 2010; 273:53-59.
27. Mukherjea D, Jajoo S, Kaur T, et al. Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat. Antioxid Redox Signal 2010; 13:589-598.
28. Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 2010; 28:478-485.
29. Chiusolo A, Defazio R, Zanetti E, et al. Kidney injury molecule-1 expression in rat proximal tubule after treatment with segment-specific nephrotoxicants: a tool for early screening of potential kidney toxicity. Toxicol Pathol 2010; 38:338-345.
30. Hoffmann D, Adler M, Vaidya VS, et al. Performance of novel kidney biomar-kers in preclinical toxicity studies. Toxicol Sci 2010; 116:8-22.
31. Fernandes I, Zhang Y, Qi Y, et al. Impact of reduced nephron mass on cyclosporine-and/or sirolimus-induced nephrotoxicity. Transplantation 2009; 88:1323-1331.
32. Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification sub-mission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol 2010; 28:455-462.
33. Mattes WB, Walker EG, Abadie E, et al. Research at the interface of industry, academia and regulatory science. Nat Biotechnol 2010; 28:432-433.
34. Warnock DG, Peck CC. A roadmap for biomarker qualification. Nat Biotechnol 2010; 28:444-445.
35. Goodsaid F, Papaluca M. Evolution of biomarker qualification at the health authorities. Nat Biotechnol 2010; 28:441-443
36. Ozer JS, Dieterle F, Troth S, et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol 2010; 28:486-494.
37. Yu Y, Jin H, Holder D, et al. Urinary biomarkers trefoil factor 3 and albumin enableearlydetection ofkidneytubularinjury. Nat Biotechnol 2010; 28:470-477.
38. Sistare FD, Dieterle F, Troth S, et al. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat Biotechnol 2010; 28:446-454.
39. Dieterle F, Perentes E, Cordier A, et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 2010; 28:463-469.
40. Han WK, Wagener G,Zhu Y, et al. Urinary biomarkersin theearlydetection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 2009; 4:873-882.
41. Liang XL, Liu SX, Chen YH, et al. Combination ofurinary kidney injury molecule-1 and interleukin-18 asearlybiomarkerforthediagnosisand progressiveassess-ment of acute kidney injury following cardiopulmonary bypass surgery: a prospective nested case-control study. Biomarkers 2010; 15:332-339.
42. Koyner JL, Vaidya VS, Bennett MR, et al. Urinary biomarkers in the clinical prognosisand earlydetection ofacute kidney injury.Clin J Am Soc Nephrol (in press).
43. Szeto CC, Kwan BC, Lai KB, et al. Urinary expression of kidney injury markers in renal transplant recipients. Clin J Am Soc Nephrol (in press).
44. Schroppel B, Kruger B, Walsh L, et al. Tubular expression of KIM-1 does not predict delayed function after transplantation. J Am Soc Nephrol 2010; 21:536-542.
45. Damman K, Van Veldhuisen DJ, Navis G, et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 2010; 96:1297-1302.
46. Von Eynatten M, Baumann M, Heemann U, et al. Urinary L-FABPand anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest 2010; 40:95-102.
47. Waanders F, Vaidya VS, van Goor H, et al. Effect of renin-angiotensin- aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis 2009; 53:16-25.
48. Kramer AB, van Timmeren MM, Schuurs TA, et al. Reduction of proteinuria in adriamycin-induced nephropathy is associated with reduction of renal kidney injury molecule (Kim-1) over time. Am J Physiol Renal Physiol 2009; 296: F1136-F1145.
49. Rees A J, Kain R. Kim-1/Tim-1: from biomarkertotherapeutic target? Nephrol Dial Transplant 2008; 23:3394-3396.
50. Waanders F, vanTimmeren MM, Stegeman CA, et al. Kidneyinjurymolecule-1 in renal disease.J Pathol 2010; 220:7-16.